RemeGen Obtains Positive Phase III Results for New Drug Telitacicept(RC18)

RemeGen announced the positive results in a phase III clinical study of Telitacicept (RC18) for the treatment of rheumatoid arthritis (RA) in China. 

This new drug application was based on a rigorous randomized, double-blind, placebo-controlled, multi-center Phase III clinical trial that enrolled a total of 479 patients with rheumatoid arthritis.

Telitacicept is a proprietary fusion protein designed to target autoimmune diseases. It consists of the extracellular domain of the human transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) receptor, combined with the fragment crystallizable (Fc) domain of human immunoglobulin G (IgG). 

Telitacicept targets two crucial cell-signaling molecules that play pivotal roles in B-lymphocyte development: B-cell lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL). By doing so, it effectively reduces B-cell mediated autoimmune responses, which are implicated in numerous autoimmune diseases.

Rheumatoid arthritis (RA) is a chronic autoimmune condition characterized primarily by erosive arthritis and affects a substantial number of individuals worldwide. The positive outcomes of Telitacicept's phase III clinical trial offer a promising new therapeutic option for RA patients globally. This innovative treatment has the potential to alleviate the burden of RA and enhance the quality of life for those living with this condition.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!